{"id":"imatinib-maintenance","safety":{"commonSideEffects":[{"rate":"50-60","effect":"Nausea"},{"rate":"30-40","effect":"Vomiting"},{"rate":"40-50","effect":"Diarrhea"},{"rate":"20-30","effect":"Abdominal pain"},{"rate":"20-30","effect":"Fatigue"},{"rate":"20-30","effect":"Muscle cramps"},{"rate":"10-20","effect":"Rash"},{"rate":"10-20","effect":"Fluid retention/edema"},{"rate":"10-30","effect":"Myelosuppression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Imatinib selectively inhibits the BCR-ABL fusion protein tyrosine kinase, which is constitutively active in chronic myeloid leukemia (CML) and drives uncontrolled cell division. By blocking this kinase activity, imatinib induces apoptosis in leukemic cells and restores normal hematopoiesis. Maintenance therapy with imatinib is used to sustain remission and prevent relapse in patients who have achieved response.","oneSentence":"Imatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and other oncogenic kinases to prevent cancer cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:18.042Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML) maintenance therapy"},{"name":"Gastrointestinal stromal tumor (GIST) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT07493408","phase":"PHASE2","title":"Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-30","conditions":"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia, Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)","enrollment":45},{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT05306301","phase":"PHASE2","title":"Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2022-10-05","conditions":"Chemotherapy, Leukemia, Acute Lymphoblastic","enrollment":32},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT03589326","phase":"PHASE3","title":"A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2018-10-04","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)","enrollment":245},{"nctId":"NCT04070443","phase":"PHASE2","title":"Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Leon Berard","startDate":"2019-11-13","conditions":"Philadelphia Chromosome Positive CML, BCR-ABL Positive Chronic Myelogenous Leukemia","enrollment":170},{"nctId":"NCT01316250","phase":"NA","title":"Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2010-08","conditions":"Chronic Myelogenous Leukemia","enrollment":13},{"nctId":"NCT05071482","phase":"PHASE4","title":"Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL","status":"TERMINATED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-09-16","conditions":"Acute Leukemia","enrollment":39},{"nctId":"NCT06628739","phase":"","title":"Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2017-07-01","conditions":"Gastrointestinal Stromal Tumor, Malignant","enrollment":168},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT02260505","phase":"PHASE3","title":"Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2014-12-24","conditions":"Gastrointestinal Stromal Tumors, Resected Gastrointestinal Stromal Tumors, Non-metastatic","enrollment":136},{"nctId":"NCT06175702","phase":"","title":"Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2023-12-25","conditions":"Lymphoblastic Leukemia, Philadelphia-Positive ALL, Adult ALL","enrollment":150},{"nctId":"NCT05009927","phase":"PHASE2","title":"Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2022-01-03","conditions":"Metastatic Gastrointestinal Stromal Tumor (GIST), C-KIT Mutation, Advanced Gastrointestinal Stromal Tumor (GIST)","enrollment":50},{"nctId":"NCT01616238","phase":"PHASE2","title":"A Study for Older Adults With Acute Lymphoblastic Leukaemia","status":"COMPLETED","sponsor":"University College, London","startDate":"2012-12","conditions":"Acute Lymphoblastic Leukaemia","enrollment":126},{"nctId":"NCT00002514","phase":"PHASE3","title":"Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1993-05-07","conditions":"Leukemia","enrollment":1929},{"nctId":"NCT05273242","phase":"PHASE4","title":"Add-on Study on WHO Solidarity Trial Plus for COVID-19 in Nepal","status":"UNKNOWN","sponsor":"Nepal Health Research Council","startDate":"2021-12-06","conditions":"COVID-19","enrollment":400},{"nctId":"NCT00509093","phase":"PHASE2","title":"Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2008-10","conditions":"Leukemia","enrollment":32},{"nctId":"NCT02611492","phase":"PHASE3","title":"A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04","conditions":"Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia","enrollment":265},{"nctId":"NCT01429610","phase":"PHASE2","title":"Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2011-11","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":78},{"nctId":"NCT02204722","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients","status":"TERMINATED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2014-10-13","conditions":"Chronic Myeloid Leukemia","enrollment":55},{"nctId":"NCT03241199","phase":"PHASE2","title":"The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2017-08-01","conditions":"Chronic Myeloid Leukemia, Philadelphia Chromosome Positive CML","enrollment":15},{"nctId":"NCT01073436","phase":"","title":"Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-05","conditions":"Chronic Myeloid Leukemia","enrollment":7},{"nctId":"NCT00114959","phase":"PHASE2","title":"Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)","status":"TERMINATED","sponsor":"ChemGenex Pharmaceuticals","startDate":"2005-10","conditions":"Myeloid Leukemia, Chronic, Myeloid Leukemia, Chronic, Accelerated-Phase, Blast Phase","enrollment":15},{"nctId":"NCT00367861","phase":"PHASE3","title":"Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2002-05","conditions":"Sarcoma, Gastro-intestinal Stromal Tumors (GIST)","enrollment":564},{"nctId":"NCT00425646","phase":"PHASE2","title":"Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-11","conditions":"Lung Cancer","enrollment":50},{"nctId":"NCT00248482","phase":"PHASE2","title":"Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2002-02","conditions":"Lung Cancer","enrollment":6},{"nctId":"NCT01665001","phase":"PHASE2","title":"Personalized Therapy of Precursor Lymphoid Neoplasms","status":"UNKNOWN","sponsor":"Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice","startDate":"2012-08","conditions":"Precursor Lymphoid Neoplasms","enrollment":200},{"nctId":"NCT01003054","phase":"PHASE2","title":"Autologous Transplantation for Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-03","conditions":"Chronic Myelogenous Leukemia","enrollment":24},{"nctId":"NCT00250042","phase":"PHASE2","title":"A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec","status":"COMPLETED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2004-04","conditions":"Leukemia, Other, Cancer","enrollment":6},{"nctId":"NCT00156286","phase":"PHASE2","title":"Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2002-03","conditions":"Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT00327262","phase":"PHASE3","title":"Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase","status":"UNKNOWN","sponsor":"Central European Leukemia Study Group","startDate":"2004-01","conditions":"Chronic Myeloid Leukemia","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Glivec","Imatinib mésilate"],"phase":"phase_3","status":"active","brandName":"Imatinib maintenance","genericName":"Imatinib maintenance","companyName":"Centre Leon Berard","companyId":"centre-leon-berard","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and other oncogenic kinases to prevent cancer cell proliferation. Used for Chronic myeloid leukemia (CML) maintenance therapy, Gastrointestinal stromal tumor (GIST) maintenance therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}